4/19/2024

Eptifibatide Injection

Products Affected - Description

- Eptifibatide injection, Amneal, 0.75 mg/mL, 100 mL vial, 1 count, NDC 70121-1003-01
- Eptifibatide injection, Amneal, 2 mg/mL, 10 mL vial, 1 count, NDC 70121-1002-01
- Eptifibatide injection, Baxter, 0.75 mg/mL, 100 mL vial, 1 count, NDC 00338-9558-10
- Eptifibatide injection, Eugia US, 0.75 mg/mL, 100 mL vial, 1 count, NDC 55150-0218-99
- Eptifibatide injection, Eugia US, 2 mg/mL, 10 mL vial, 1 count, NDC 55150-0219-10
- Eptifibatide injection, Eugia US, 2 mg/mL, 100 mL vial, 1 count, NDC 55150-0220-99
- Eptifibatide injection, Sagent, 0.75 mg/mL, 100 mL vial, 1 count, NDC 70860-0305-51
- Eptifibatide injection, Sagent, 2 mg/mL, 10 mL vial, 1 count, NDC 25021-0409-10

Reason for the Shortage

- Accord has temporarily discontinued eptifibatide injection.
- Akorn ceased operations in February 2023.
- Amneal did not provide a reason for the shortage.
- Baxter states the shortage is due to increased demand.
- Eugia did not provide a reason for the shortage.
- Merck discontinued Integrilin in October 2020. Wholesalers may continue to sell inventory until product expires.
- Viatris has eptifibatide injection available.
- Sagent states the shortage is due to manufacturing delay.
- Slate Run has eptifibatide injection available.

Available Products

- Eptifibatide injection, Mylan Institutional (Viatris), 0.75 mg/mL, 100 mL vial, 1 count, NDC 67457-0631-10
- Eptifibatide injection, Mylan Institutional (Viatris), 2 mg/mL, 10 mL vial, 1 count, NDC 67457-0629-10
- Eptifibatide injection, Mylan Institutional (Viatris), 2 mg/mL, 100 mL vial, 1 count, NDC 67457-0630-10
- Eptifibatide injection, Sagent, 0.75 mg/mL, 100 mL vial, 1 count, NDC 25021-0408-51
- Eptifibatide injection, Slate Run Pharmaceuticals, 0.75 mg/mL, 100 mL vial, 1 count, NDC 70436-0027-80
- Eptifibatide injection, Slate Run Pharmaceuticals, 2 mg/mL, 10 mL vial, 1 count, NDC 70436-0026-80

Estimated Resupply Dates

- Amneal has eptifibatide 0.75 mg/mL 100 mL vials and 2 mg/mL in 10 mL vials on long-term back order and the company cannot estimate a release date.
- Baxter has eptifibatide 0.75 mg/mL in 100 mL vials on back order and the company estimates a release date in June 2024.
- Eugia has all eptifibatide injection presentations on intermittent back order and the company is releasing supplies as they become available.
- Sagent has eptifibatide 2 mg/mL 10 mL vials on back order and the company cannot estimate a release date. The 0.75 mg/mL 100 mL vials (NDC 70860-0305-51) are also on back order and the company cannot estimate a release date.

Updated

Updated April 19, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. Created May 21, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.